A5100714113- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Acute Lymphoblastic Leukemia research
- Neuroendocrine Tumor Research Advances
- Immunodeficiency and Autoimmune Disorders
- COVID-19 and healthcare impacts
- Biosimilars and Bioanalytical Methods
- Cerebrovascular and Carotid Artery Diseases
- Reproductive Health and Technologies
- Infection Control and Ventilation
- Monoclonal and Polyclonal Antibodies Research
- Airway Management and Intubation Techniques
- Traumatic Brain Injury and Neurovascular Disturbances
- Advanced MRI Techniques and Applications
- Total Knee Arthroplasty Outcomes
- Orthopaedic implants and arthroplasty
- COVID-19 and Mental Health
- Retinal Imaging and Analysis
- Health, Environment, Cognitive Aging
- Pelvic floor disorders treatments
The Ohio State University
1995-2024
Brigham and Women's Hospital
2019-2024
Stanford Health Care
2024
Sidney Kimmel Comprehensive Cancer Center
2022-2024
Johns Hopkins University
2022-2024
Harvard University
2015-2024
University of California, Los Angeles
2022-2023
Albert Einstein College of Medicine
2019-2023
University of Wisconsin–Milwaukee
2023
University of New Brunswick
2022
Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies acceptable side-effect profiles needed for this patient population. In multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor delta isoform phosphatidylinositol 3-kinase, in combination rituximab versus plus placebo. We...
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas.
Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib. Methods Twenty-four CLL lymphodepleting chemotherapy CAR-T cells at one three dose levels (2 × 105, 2 106, or 107 cells/kg). Nineteen experienced disease progression while receiving ibrutinib, were ibrutinib intolerant, two did not experience Six venetoclax refractory, 23 a complex...
Chimeric antigen receptor (CAR) T cells can induce remission in highly refractory leukemia and lymphoma subjects, yet the parameters for achieving sustained relapse-free survival are not fully delineated.We analyzed 43 pediatric young adult subjects participating a Phase I trial of defined composition CD19CAR (NCT02028455). CAR cell phenotype, function expansion, as well starting material repertoire, were relation to therapeutic outcome (defined complete within 63 days) duration free B...
Background-Shortages of personal protective equipment (PPE) including N95 filtering facepiece respirators is an urgent concern in the setting global COVID-19 pandemic. Decontamination PPE could be useful to maintain adequate supplies, but there uncertainty regarding efficacy decontamination technologies.Methods-A modification American Society for Testing and Materials standard quantitative carrier disk test method (ASTM E-2197-11) was used examine effectiveness ultraviolet-C (UV-C) light, a...
To evaluate the long-term efficacy and safety of repeat onabotulinumtoxinA injections in patients inadequately managed by anticholinergics for urinary incontinence (UI) due to neurogenic detrusor overactivity.Patients who completed either 2 preceding phase III studies were offered entry into an extension study received 200 U or 300 U. The data integrated across ongoing studies. present interim analysis included all ≥ 1 treatment. analyzed treatment cycle (cycles 1-5). primary assessment was...
Cardiovascular disease (CVD) risk is increased in SLE and underestimated by general population prediction algorithms. We aimed to develop a novel SLE-specific tool, SLECRISK, provide more accurate estimate of CVD SLE.
7003 Background: Signals through PI3K-delta regulate activation, proliferation and survival of B cells, critically influence homing retention cells in lymphoid tissues, are hyperactive many BEcell malignancies. Idelalisib (GS-1101) is a first-in-class, selective, oral inhibitor PI3Kδ that reduces proliferation, enhances apoptosis, inhibits malignant cells. Methods: Pts with relapsed/refractory CLL were treated continuously single-agent idelalisib from 50E350 mg/dose (QD or BID). Response...
The COVID-19 pandemic has resulted in a dramatic increase the number of patients requiring prolonged mechanical ventilation. Few studies have reported specific tracheotomy outcomes, and optimal timing patient selection criteria for remains undetermined. We delineate our outcomes tracheotomies performed on during peak at major epicenter United States.This is retrospective observational cohort study. Mortality, ventilation liberation rate, complication decannulation rate were...
7014 Background: Ibrutinib interacts covalently with cysteine 481 of Bruton tyrosine kinase (BTK), resulting in targeted inhibition B cell receptor signaling. Early trials ibrutinib mono- or combination therapy enrolled 246 CLL patients receiving a median 14 months ibrutinib. 20 (8%) experienced progressive disease (PD), including 8 Richter's transformation. Here we examine changes to the genome 3 that acquired resistance Methods: was defined as achieving partial response (PR) better lasting...
7017 Background: PI3K-delta signaling is critical for proliferation, survival, homing and tissue retention of malignant B cells. Idelalisib a first-in-class, selective, oral inhibitor PI3Kδ that has shown considerable monotherapy activity in pts with heavily pretreated CLL. Methods: This phase I study evaluated idelalisib continuously given at 150 mg BID combination rituximab (R, 375 mg/m 2 every wk x 8), bendamustine (B, 70 or 90 2, 4 wks 6) BR (every relapsed/refractory Pts still on...
7024 Background: CD19-specific chimeric antigen receptor (CAR) modified T cells produce high anti-tumor activity in relapsed or refractory (R/R) ALL, but can be associated with cytokine release syndrome (CRS) and neurotoxicity (NTX). Herein, we report baseline post-treatment clinical laboratory factors severe NTX (≥Grade 3) our phase I trial of 19-28z CAR for adult patients (pts) R/R B-ALL (NCT01044069). Methods: 51 pts were treated following conditioning chemotherapy at MSKCC. In order to...
102 Background: We are conducting a phase I/II trial in which patients (pts) with relapsed or refractory (R/R) CD19+ B cell malignancies receive CD19 CAR-T cells comprised of defined ratio CD8+ and CD4+ cells. Methods: Pts received lymphodepleting chemotherapy followed by infusion 1:1 CD8+:CD4+ at one 3 dose levels (2x105 to 2x107 cells/kg). No pts were excluded due lymphopenia (ALC < 0.5 22% pts), circulating tumor poor vitro T proliferation. Results: Ninety ALL (n = 36), NHL 41) CLL 13)...
SLE is associated with high risks of cardiovascular disease (CVD) and mortality, has a wide spectrum presentations. We investigated whether severity at diagnosis was CVD or mortality risk.Within Medicaid (2000-10), we identified patients 18-65 years age incident SLE. Initial classified-mild, moderate, severe-during the baseline year prior to start follow-up (incident index date) using published algorithm based on SLE-related medications diagnoses. Patients were followed from date first event...
Abstract We demonstrate that inhibition of cyclin-dependent kinases 4/6 (CDK4/6) leads to senescence in human papillomavirus (HPV)–negative (−) head and neck squamous cell carcinoma (HNSCC), but not HPV-positive (+) HNSCC. The BCL-2 family inhibitor, navitoclax, has been shown eliminate senescent cells effectively. evaluated the efficacy combining palbociclib navitoclax HPV− Three HNSCC lines (CAL27, HN31, PCI15B) three HPV+ (UPCI-SCC-090, UPCI-SCC-154, UM-SCC-47) were treated with...